Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says

MT Newswires Live

Apr 07

Entrada Therapeutics (TRDA) management expressed confidence ahead of a Q2 data readout for its ENTR-601-44 Duchenne muscular dystrophy program, highlighting differentiated data from its endosomal escape platform and a favorable safety profile, Oppenheimer said in a Monday note.

The analysts said preclinical and healthy volunteer data suggest stronger efficacy versus a key competitor, with management expecting double-digit dystrophin levels at 6 mg per kilogram and potentially best-in-class outcomes at higher dosing.

Oppenheimer added that the upcoming Q2 readout could drive more than 50% upside for the stock if the data confirm platform differentiation.

The firm raised the probability of success for ENTR-601-44 to 45% from 40%, reiterated its outperform rating and increased its price target to $23.

Shares of Entrada were up nearly 3% in Monday trading.

Price: 13.48, Change: +0.33, Percent Change: +2.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2625670490"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625670490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625670490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625670490","market":"nz","top_or_hot":-1,"title":"Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRDA) management expressed confidence ahead of a Q2 data readout for its ENTR-601-44 Duchenne muscular dystrophy program, highlighting differentiated data from its endosomal escape platform and a favorable safety profile, Oppenheimer said in a Monday note.</p><p>The analysts said preclinical and healthy volunteer data suggest stronger efficacy versus a key competitor, with management expecting double-digit dystrophin levels at 6 mg per kilogram and potentially best-in-class outcomes at higher dosing.</p><p>Oppenheimer added that the upcoming Q2 readout could drive more than 50% upside for the stock if the data confirm platform differentiation.</p><p>The firm raised the probability of success for ENTR-601-44 to 45% from 40%, reiterated its outperform rating and increased its price target to $23.</p><p>Shares of Entrada were up nearly 3% in Monday trading.</p><p>Price: 13.48, Change: +0.33, Percent Change: +2.51</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-07 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRDA) management expressed confidence ahead of a Q2 data readout for its ENTR-601-44 Duchenne muscular dystrophy program, highlighting differentiated data from its endosomal escape platform and a favorable safety profile, Oppenheimer said in a Monday note.</p><p>The analysts said preclinical and healthy volunteer data suggest stronger efficacy versus a key competitor, with management expecting double-digit dystrophin levels at 6 mg per kilogram and potentially best-in-class outcomes at higher dosing.</p><p>Oppenheimer added that the upcoming Q2 readout could drive more than 50% upside for the stock if the data confirm platform differentiation.</p><p>The firm raised the probability of success for ENTR-601-44 to 45% from 40%, reiterated its outperform rating and increased its price target to $23.</p><p>Shares of Entrada were up nearly 3% in Monday trading.</p><p>Price: 13.48, Change: +0.33, Percent Change: +2.51</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625670490","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625670490","pubTimestamp":1775491783,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Entrada Therapeutics (TRDA) management expressed confidence ahead of a Q2 data readout for its ENTR-601-44 Duchenne muscular dystrophy program, highlighting differentiated data from its endosomal esca","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","OPY":"奥本海默控股","TRDA":"Entrada Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"奥本海默表示，Entrada Therapeutics第二季度数据可能会推动平台差异化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1.5,"TRDA":1.5},"content_text":"Entrada Therapeutics (TRDA) management expressed confidence ahead of a Q2 data readout for its ENTR-601-44 Duchenne muscular dystrophy program, highlighting differentiated data from its endosomal escape platform and a favorable safety profile, Oppenheimer said in a Monday note.The analysts said preclinical and healthy volunteer data suggest stronger efficacy versus a key competitor, with management expecting double-digit dystrophin levels at 6 mg per kilogram and potentially best-in-class outcomes at higher dosing.Oppenheimer added that the upcoming Q2 readout could drive more than 50% upside for the stock if the data confirm platform differentiation.The firm raised the probability of success for ENTR-601-44 to 45% from 40%, reiterated its outperform rating and increased its price target to $23.Shares of Entrada were up nearly 3% in Monday trading.Price: 13.48, Change: +0.33, Percent Change: +2.51","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}